Evolving landscape of targeted therapies in early phase clinical trials
Open Access
- 12 April 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 240, 116745
Abstract
No abstract availableKeywords
Funding Information
- Gilead Foundation
- Instituto de Salud Carlos III
- Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona
This publication has 19 references indexed in Scilit:
- LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapyAnnals of Oncology, 2024
- Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal CancersThe Oncologist, 2024
- The NCI-MATCH trial: lessons for precision oncologyNature Medicine, 2023
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialThe Lancet Oncology, 2022
- Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsThe Lancet, 2022
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialNature Medicine, 2019
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyNature Medicine, 2019
- Encouraging Trends in Modern Phase 1 Oncology TrialsNew England Journal of Medicine, 2018
- Limits to Personalized Cancer MedicineNew England Journal of Medicine, 2016
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015